In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FemRx Inc.

Division of Johnson & Johnson

Latest From FemRx Inc.

Conceptus' Re-Birth: Surviving in Women's Health

The early-to-mid 1990s marked the rise of a huge wave of interest in women's health among device start-ups and investors. Several women's health companies, including Conceptus, were among the ill-fated IPO Class of 1996 that largely failed to meet investor expectations. Most of these start-ups are no longer around, but Conceptus re-trenched and shifted its emphasis from fertility to a new approach to sterilization, which finally received FDA clearance late last year. The company has survived the pitfalls that derailed other women's health start-ups, most notably a customer group that is difficult to access and slow to adopt new technology, and a challenging reimbursement environment, but in doing so, may be the exception that proves the rule.
Medical Device Strategy

Genosis Ltd.

Genosis Ltd. is developing both male and female fertility tests, which couples can use at home to help identify reproductive disorders at an earlier stage, allowing those who need in vitro fertilization to progress onto it more quickly, with better results.
Medical Device Platform Technologies

Metris Therapeutics Ltd.

Existing drug therapies for endometriosis, including drugs that block estrogen and GnRH agonists bear troubling side effects. Metris Therapeutics hopes to avoid these by taking a different path to the disease. The company's founders were among the first to identfiy increased levels of vascular endothelial growth factor (VEGF) in the peritoneal fluid of women with endometriosis. Metris has therfore set out to develop a product to block VEGF's action.
BioPharmaceutical Platform Technologies

Women's Health: Too early or Too Late?

As an industry, women's health is in its infancy. It has yet to develop beyond a collection of niche specialties in reproductive medicine and breast cancer.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Medical Devices
  • Therapeutic Areas
  • Gynecological, Urological
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Johnson & Johnson
  • Senior Management
  • Andrew M Thompson, Pres. & CEO
    Edward W Unkart, VP, Fin. & Admin. & CFO
    George M Savage, MD, SVP, R&D
  • Contact Info
  • FemRx Inc.
    Phone: (408) 752-8580
    1221 Innsbruck Dr.
    Sunnyvale, CA 94089
    USA
UsernamePublicRestriction

Register